Abstract: The invention relates to a novel technique for germinating a sproutable food such as rice, other types of cereals, or seeds. Provided is a novel germination technique capable of increasing a content of glutamate, accelerating an enrichment of gamma-aminobutyric acid, and exerting excellent functionality for the body, and a novel functional food material or pharmaceutical agent. A sprouted cereal is produced by soaking the cereal in a soaking solution prepared by addition of at least one carbonate selected from alkali metal carbonate, and alkaline earth metal carbonate to water to make the cereal absorb the soaking solution, followed by allowing the cereal to germinate under predetermined conditions.

Abstract: Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.

Abstract: The invention relates to a novel technique for germinating a sproutable food such as rice, other types of cereals, or seeds. Provided is a novel germination technique capable of increasing a content of glutamate, accelerating an enrichment of gamma-aminobutyric acid, and exerting excellent functionality for the body, and a novel functional food material or pharmaceutical agent. A sprouted cereal is produced by soaking the cereal in a soaking solution prepared by addition of at least one carbonate selected from alkali metal carbonate, and alkaline earth metal carbonate to water to make the cereal absorb the soaking solution, followed by allowing the cereal to germinate under predetermined conditions.

Abstract: The invention relates to a novel technique for germinating a sproutable food such as rice, other types of cereals, or seeds. Provided is a novel germination technique capable of increasing a content of glutamate, accelerating an enrichment of gamma-aminobutyric acid, and exerting excellent functionality for the body, and a novel functional food material or pharmaceutical agent. A sprouted cereal is produced by soaking the cereal in a soaking solution prepared by addition of at least one carbonate selected from alkali metal carbonate, and alkaline earth metal carbonate to water to make the cereal absorb the soaking solution, followed by allowing the cereal to germinate under predetermined conditions.

Abstract: Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.

Abstract: The invention relates to a novel technique for germinating a sproutable food such as rice, other types of cereals, or seeds. Provided is a novel germination technique capable of increasing a content of glutamate, accelerating an enrichment of gamma-aminobutyric acid, and exerting excellent functionality for the body, and a novel functional food material or pharmaceutical agent. A sprouted cereal is produced by soaking the cereal in a soaking solution prepared by addition of at least one carbonate selected from alkali metal carbonate, and alkaline earth metal carbonate to water to make the cereal absorb the soaking solution, followed by allowing the cereal to germinate under predetermined conditions.

Abstract: A method for the treatment of cerebrovascular contraction in mammals involving administration of a pharmaceutical composition containing as an effective ingredient a p-guanidinobenzoic acid derivative represented by the formula ##STR1## wherein R denotes a group represented by the formula ##STR2## or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.